BACKGROUND: Multiple sclerosis (MS) is characterised by inflammatory lesions of the central nervous system. Interferon beta-1b (IFNB-1b) has been shown to improve clinical and magnetic resonance imaging (MRI) measures for patients with MS. OBJECTIVE: To evaluate whether IFNB-1b in patients presenting with clinically isolated syndromes (CIS) prevented persisting T1 hypointensities on MRI (persistent black holes (PBHs)). METHODS: In the placebo-controlled phase, patients (n = 468) were initially randomised to IFNB-1b (n = 292) or placebo (n = 176) for two years or clinically definite MS (CDMS). In the open-label phase (n = 418), both groups were offered IFNB-1b for up to five years. Lesions were classified as PBHs if T1 hypointensity persisted throughout the last available scan (minimum time one year). RESULTS: A total of 435 patients were evaluable for analysis. The number of PBHs/patient was lower in the early rather than the delayed treatment arm during both phases (.42 vs .71, p = .0102 and .70 vs 1.17, p = .0121). Exploratory analyses identified baseline characteristics that affected rate of conversion. CONCLUSIONS: Although the rate of lesions that converted to PBH showed no significant differences between groups, the numbers of PBHs per patient out of new lesions was significantly lower in IFNB-1b patients compared to patients on placebo. TRIAL REGISTRATION NUMBER: NCT00544037.
RCT Entities:
BACKGROUND:Multiple sclerosis (MS) is characterised by inflammatory lesions of the central nervous system. Interferon beta-1b (IFNB-1b) has been shown to improve clinical and magnetic resonance imaging (MRI) measures for patients with MS. OBJECTIVE: To evaluate whether IFNB-1b in patients presenting with clinically isolated syndromes (CIS) prevented persisting T1 hypointensities on MRI (persistent black holes (PBHs)). METHODS: In the placebo-controlled phase, patients (n = 468) were initially randomised to IFNB-1b (n = 292) or placebo (n = 176) for two years or clinically definite MS (CDMS). In the open-label phase (n = 418), both groups were offered IFNB-1b for up to five years. Lesions were classified as PBHs if T1 hypointensity persisted throughout the last available scan (minimum time one year). RESULTS: A total of 435 patients were evaluable for analysis. The number of PBHs/patient was lower in the early rather than the delayed treatment arm during both phases (.42 vs .71, p = .0102 and .70 vs 1.17, p = .0121). Exploratory analyses identified baseline characteristics that affected rate of conversion. CONCLUSIONS: Although the rate of lesions that converted to PBH showed no significant differences between groups, the numbers of PBHs per patient out of new lesions was significantly lower in IFNB-1b patients compared to patients on placebo. TRIAL REGISTRATION NUMBER: NCT00544037.
Entities:
Keywords:
Interferon beta-1b; MRI; T1 hypointensity; black holes
Authors: Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman Journal: Nat Rev Neurol Date: 2015-09-15 Impact factor: 42.937
Authors: Maria Di Gregorio; Lorenzo Gaetani; Paolo Eusebi; Piero Floridi; Antonella Picchioni; Giovanni Rosi; Andrea Mancini; Chiara Floridi; Francesca Baschieri; Lucia Gentili; Paola Sarchielli; Paolo Calabresi; Massimiliano Di Filippo Journal: J Neurol Date: 2018-01-11 Impact factor: 4.849
Authors: Kassandra L Munger; Karl Köchert; Kelly C Simon; Ludwig Kappos; Chris H Polman; Mark S Freedman; Hans P Hartung; David H Miller; Xavier Montalbán; Gilles Edan; Frederik Barkhof; Dirk Pleimes; Rupert Sandbrink; Alberto Ascherio; Christoph Pohl Journal: Ann Clin Transl Neurol Date: 2014-08-22 Impact factor: 4.511
Authors: Robert Zivadinov; Michael G Dwyer; Deepa P Ramasamy; Mat D Davis; Joshua R Steinerman; Omar Khan Journal: J Neuroimaging Date: 2015-09-22 Impact factor: 2.486
Authors: Maria Liguori; Antonio Qualtieri; Carla Tortorella; Vita Direnzo; Angelo Bagalà; Mariangela Mastrapasqua; Patrizia Spadafora; Maria Trojano Journal: PLoS One Date: 2014-08-06 Impact factor: 3.240